ACADIA PHARMACEUTICALS INC. (ACAD)

Every figure this model derived for ACAD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 14,694,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 956,474,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,224,545,000 AssetsCurrent 2026-06-30
current liabilities 361,436,000 LiabilitiesCurrent 2026-06-30
equity 1,306,609,000 StockholdersEquity 2026-06-30
ocf 109,836,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 1,138,643,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 58,053,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ACAD on one particular measure came for.

RatioValue
cash operating margin12.78
current ratio3.39
current ratio reported3.39
dilution pct2.14
ebit yoy-63.53
fcf margin8.36
growth cv0.67
operating margin7.59
owner earnings margin3.26
revenue growth11.75
revenue growth per share9.41
roic19.49
rule of 4019.34
sbc pct revenue5.1

What to be careful about

What this model itself distrusts about ACAD's figures. Written by the derivation as it ran, not added afterwards.